We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Canadian Stroke Network. Descriptive analysis of tPAuse for strokein phase 1 and 2 of the registry of the Canadian Stroke Network. Can J Neurol Sci2005;32 (In print)Google Scholar
2
2.Katzan, IL, Furlan, AJ, Lloyd, LE, et al.Use of tissue-typeplasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA2000;283:1151–1158.Google Scholar
3
3.Riopelle, RJ, Howse, DC, Bolton, C, et al.Regional access to acuteischemic stroke intervention. Stroke2001;32:652–655.Google Scholar
4
4.Merino, JG, Silver, B, Wong, E, et al.Extending tissue plasminogenactivator use to community and rural stroke patients. Stroke2002;33:141–146.Google Scholar
5
5.Grotta, JC, Burgin, WS, El-Mitwalli, A, et al.Intravenous tissue-typeplasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol2001;58:2009–2013.Google Scholar
6
6.Saposnik, G, Young, B, Silver, B, et al.Lack of improvement inpatients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA2004;292:1839–1844.Google Scholar
7
7.Alberts, MJ, Hademenos, G, Latchaw, RE, et al.Recommendationsfor the establishment of primary stroke centers. Brain Attack Coalition. JAMA2000;283:3102–3109.CrossRefGoogle Scholar
9.Adams, HPJr, Brott, TG, Furlan, AJ, et al.Guidelines forThrombolytic Therapy for Acute Stroke: a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke1996;27:1711–1718.Google Scholar
10
10.Chapman, KM, Woolfenden, AR, Graeb, D, et al.Intravenous tissueplasminogen activator for acute ischemic stroke: A Canadianhospital's experience. Stroke2000;31:2920–2924.Google Scholar
11
11.Albers, GW, Bates, VE, Clark, WM, et al.Intravenous tissue-typeplasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA2000;283:1145–1150.CrossRefGoogle ScholarPubMed
12
12.Marler, JR, Tilley, BC, Lu, M, et al.Early stroke treatment associatedwith better outcome: the NINDS rt-PA stroke study. Neurology2000;55:1649–1655.CrossRefGoogle Scholar
13
13.Tanne, D, Bates, VE, Verro, P, et al.Initial clinical experience with IVtissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology1999;53:424–427.Google Scholar
14
14.Hacke, W, Donnan, G, Fieschi, C, et al.Association of outcome withearly stroke treatment: pooled analysis of ATLANTIS, ECASS,and NINDS rt-PA stroke trials. Lancet2004;363:768–774.Google Scholar
15
15.Adams, H, Adams, R, Del Zoppo, G, Goldstein, LB. Guidelines for theearly management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke2005;36:916–923.Google Scholar
16
16.Tu, JV, Willison, DJ, Silver, FL, et al.Impracticability of informedconsent in the Registry of the Canadian Stroke Network. N Engl J Med2004;350:1414–1421.Google Scholar
17
17.Hill, MD, Buchan, AM. Thrombolysis for acute ischemic stroke:results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ2005;172:1307–1312.Google Scholar